Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation

BACKGROUND: Retrospective studies suggest a survival benefit when platinum-based chemotherapy is administered to patients with pancreatic cancer harbouring a germline mutation in BRCA1, BRCA2 or PALB2 (mut-positive PDAC). However, the objective response rate (ORR) and real-world progression free sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Wattenberg, Max M., Asch, Daniella, Yu, Shun, O’Dwyer, Peter J., Domchek, Susan M., Nathanson, Katherine L., Rosen, Mark A., Beatty, Gregory L., Siegelman, Evan S., Reiss, Kim A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000723/
https://www.ncbi.nlm.nih.gov/pubmed/31787751
http://dx.doi.org/10.1038/s41416-019-0582-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000723/
https://www.ncbi.nlm.nih.gov/pubmed/31787751
http://dx.doi.org/10.1038/s41416-019-0582-7

Ejemplares similares